{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:10:20Z","timestamp":1759590620473,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PGC2018-096956-B-C43"],"award-info":[{"award-number":["PGC2018-096956-B-C43"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clineuro.2021.106847","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T11:41:15Z","timestamp":1627386075000},"page":"106847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Age at sampling and sex distribution of AChRAb vs. MuSKAb myasthenia gravis in a large Greek population"],"prefix":"10.1016","volume":"208","author":[{"given":"Maria","family":"Belimezi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Kalliaropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4935-438X","authenticated-orcid":false,"given":"Irene","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexios-Fotios A.","family":"Mentis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George P.","family":"Chrousos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2021.106847_bib1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/acn3.51309","article-title":"Human leukocyte antigen class II associations in late-onset myasthenia gravis","volume":"8","author":"Spagni","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clineuro.2021.106847_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2021.106847_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clineuro.2018.06.041","article-title":"Clinical characteristics of AChRAb and MuSKAb double seropositive myasthenia gravis patients","volume":"172","author":"Li","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.clineuro.2021.106847_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.nmd.2020.03.012","article-title":"AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review","volume":"30","author":"Lu","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clineuro.2021.106847_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/jnnp.71.3.352","article-title":"Epidemiology of seropositive myasthenia gravis in Greece","volume":"71","author":"Poulas","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2021.106847_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000080093","article-title":"Incidence of myasthenia gravis in the Province of Ferrara","volume":"23","author":"Casetta","year":"2004","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.clineuro.2021.106847_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/01616412.2018.1525121","article-title":"Clinical differences of early and late-onset myasthenia gravis in 985 patients","volume":"41","author":"Fan","year":"2019","journal-title":"Neurol. Res."},{"key":"10.1016\/j.clineuro.2021.106847_bib8","first-page":"1","article-title":"Myasthenia gravis in Poland: National Healthcare Database Epidemiological Study","author":"Sobieszczuk","year":"2021","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.clineuro.2021.106847_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.clineuro.2021.106847_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(05)71337-4","article-title":"The gender gap in autoimmune disease","volume":"357","author":"Poulas","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2021.106847_bib11","doi-asserted-by":"crossref","first-page":"J109","DOI":"10.1016\/j.jaut.2011.10.003","article-title":"Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity","volume":"38","author":"Quintero","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clineuro.2021.106847_bib12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1212\/WNL.54.5.1202","article-title":"Equal male and female incidence of myasthenia gravis","volume":"54","author":"Poulas","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2021.106847_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420949808","article-title":"Gender issues of antibody-mediated diseases in neurology: (NMOSD\/autoimmune encephalitis\/MG)","volume":"13","author":"Altintas","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2021.106847_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/00207454.2018.1529669","article-title":"A tri-modal distribution of age-of-onset in female patients with myasthenia gravis is associated with the gender-related clinical differences","volume":"129","author":"Asmail","year":"2019","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.clineuro.2021.106847_bib15","article-title":"Gender and ethnicity based differences in clinical and laboratory features of myasthenia gravis","volume":"2015","author":"Abukhalil","year":"2015","journal-title":"Autoimmun. Dis."},{"key":"10.1016\/j.clineuro.2021.106847_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ane.13239","article-title":"Incidence of AChR Ab-positive myasthenia gravis in Israel: a population-based study","volume":"142","author":"Lotan","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.clineuro.2021.106847_bib17","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00415-020-10342-3","article-title":"Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?","volume":"268","author":"Monte","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2021.106847_bib18","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2021.106847_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1196\/annals.1405.040","article-title":"Myasthenia gravis in the elderly: is it different?","volume":"1132","author":"Aarli","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clineuro.2021.106847_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/jnnp.2006.100545","article-title":"Clinical and serological study of myasthenia gravis in HuBei Province, China","volume":"78","author":"Zhang","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2021.106847_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2012.10.028","article-title":"Myasthenia gravis in the elderly","volume":"325","author":"Hellmann","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2021.106847_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/mus.27120","article-title":"The Duke myasthenia gravis clinic registry: I. Description and demographics","volume":"63","author":"Sanders","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2021.106847_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneuroim.2017.04.003","article-title":"Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel","volume":"307","author":"Asmail","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2021.106847_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2021.106847_bib25","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1210\/en.2004-1003","article-title":"Differential estrogen receptor expression in autoimmune myasthenia gravis","volume":"146","author":"Nancy","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.clineuro.2021.106847_bib26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"Longitudinal effects of aging on serum total and free testosterone levels in healthy men","volume":"86","author":"Harman","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clineuro.2021.106847_bib27","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.4049\/jimmunol.175.8.5050","article-title":"Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses","volume":"175","author":"Delpy","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.clineuro.2021.106847_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1515\/cclm-2012-0849","article-title":"Gender medicine: a task for the third millennium","volume":"51","author":"Baggio","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clineuro.2021.106847_bib29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clineuro.2021.106847_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2021.106847_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"long-lasting rituximab-induced reduction of specific\u2014but not total\u2014IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clineuro.2021.106847_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.11.004","article-title":"Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis","volume":"218","author":"Provenzano","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2021.106847_bib33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/01.LAB.0000028144.48023.9B","article-title":"Anti-p110 autoantibodies identify a subtype of \u201cseronegative\u201d myasthenia gravis with prominent oculobulbar involvement","volume":"82","author":"Scuderi","year":"2002","journal-title":"Lab. Investig."},{"key":"10.1016\/j.clineuro.2021.106847_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9646209","article-title":"Serological immunoglobulin-free light chain profile in myasthenia gravis patients","volume":"2018","author":"Basile","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.clineuro.2021.106847_bib35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of juvenile myasthenia gravis","volume":"11","author":"O'Connell","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2021.106847_bib36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1468-1331.2009.02624.x","article-title":"Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece","volume":"16","author":"Tsiamalos","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2021.106847_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","article-title":"Epidemiology of myasthenia gravis in Ontario, Canada","volume":"26","author":"Breiner","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clineuro.2021.106847_bib38","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","article-title":"Myasthenia gravis in South Africans: racial differences in clinical manifestations","volume":"17","author":"Heckmann","year":"2007","journal-title":"Neuromuscul. Disord."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846721003760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846721003760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:38:09Z","timestamp":1759588689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846721003760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":38,"alternative-id":["S0303846721003760"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2021.106847","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age at sampling and sex distribution of AChRAb vs. MuSKAb myasthenia gravis in a large Greek population","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2021.106847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106847"}}